Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2022
Reporting Period: The filing announces financial results for the three months ended March 31, 2022.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for the Q1 2022 results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing text does not detail specific material changes or comparative data versus the prior period. It only confirms the issuance of results for the quarter ended March 31, 2022.
Guidance, Outlook, and Management Commentary
Conference Call: Management scheduled a conference call for May 4, 2022, at 8:00 AM ET to discuss the results.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2022 revenue, net income, and cash flow figures.
- Verify the details of the conference call held on May 4, 2022, for management commentary on the results.
- Confirm the status of the company's liquidity and debt levels as disclosed in the full press release.
- Note that the 8-K text itself contains no financial data and acts solely as a notification of the results.